Portal de investigación
SEHOP-PENCIL study: Personalised mEdicine for Cancer in children in Spain.
Datos básicos
- Protocolo:
- PMP21/00073
- EUDRACT:
- NCT:
- Centro:
- Año de incio:
- 2022
- Año de finalización:
- 2026
Objetivos del proyecto
Proyecto competitivo multicéntrico con varios centros beneficiarios. Gestión solo del presupuesto IISLAFE. Coordinador Hospital Vall d´Hebrón. IP: Lucas Moreno Martin Retortillo. PRESENTADO AL CEIm COMO PROYECTO EXTERNO. REGISTRADO POR EL CEIm CON CÓDIGO 2023-659-1.
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
[Translated article] The relevance of therapeutic positioning in the post-approval evaluation of new drugs.
Alegre-Del Rey, Emilio Jesus; (...); Dominguez-Santana, Carmen Maria
Article. 10.1016/j.farma.2024.10.011. 2025
A NATIONAL PEDIATRIC NEURO-ONCOLOGY TUMOR BOARD INITIATIVE IN SPAIN: RESULTS OF A WEB-BASED SURVEY TO EVALUATE PARTICIPANT EXPERIENCE UTILIZING THIS RESOURCE
Illade, Laura; (...); Lassaletta, Alvaro
Article. 2022
A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma
Van Hal, Gertjan; (...); Lewin, Jeremy Howard
Meeting Abstract. 2023
Adolescent cancer care: What has changed in Spain in the past decade?
Garrido Colino, Carmen; (...); Vagace Valero, Jose Manuel
Article. 10.1016/j.anpede.2023.01.003. 2023
Adolescent cancer care: What has changed in Spain in the past decade?
Garrido Colino, Carmen; (...); SEHOP
Article. 10.1016/j.anpedi.2022.09.012. 2023
Alectinib in pediatric patients with solid or CNS tumors harboring ALK-fusions: Emerging pharmacokinetic data from the iMATRIX alectinib phase I/II open-label, multi-center study
Doz, Francois; (...); Gajjar, Amar J.
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.3098. 2024
ASSESSMENT OF A NOVEL READY-TO-USE TEMOZOLOMIDE ORAL SUSPENSION IN CHILDREN WITH SOLID TUMORS: RESULTS OF TEMOKIDS, A POPULATION PHARMACOKINETIC, ACCEPTABILITY AND SAFETY PHASE-1 STUDY
Abbou, Samuel; (...); Metayer, Lucy
Meeting Abstract. 2023
Barriers and facilitators to the implementation of a new European eHealth solution (SurPass v2.0): the PanCareSurPass Open Space study.
de Beijer IAE; (...); Pluijm SMF
Article. 10.1007/s11764-023-01498-8. 2023
Cancer is not a risk factor for severe COVID-19 in children, except in patients with recent allogeneic hematopoietic stem cell transplantation or comorbidities.
Velasco Puyó P; (...); Astigarraga I
Article. 10.1002/pbc.31120. 2024
Características clínicas del ingreso por enfermedad mental en una Unidad de Hospitalización Psiquiátrica Comarcal. Estudio descriptivo 2008-2018.
Olcina-Rodriguez JF; (...); Gómez-Pajares F
Article. 10.53680/vertex.v33i157.261. 2022
Comparative Multicentric Evaluation of Inter-Observer Variability in Manual and Automatic Segmentation of Neuroblastic Tumors in Magnetic Resonance Images
Veiga-Canuto, Diana; (...); Marti-Bonmati, Luis
Article. 10.3390/cancers14153648. 2022
Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP).
Gargallo, P.; (...); Moreno, L.
Article. 10.1007/s12094-021-02759-7. 2022
Childhood and Adolescent Central Nervous System Tumours in Spain: Incidence and Survival over 20 Years: A Historical Baseline for Current Assessment.
Chirlaque MD; (...); The Spanish Childhood Cancer Epidemiology Working Group
Article. 10.3390/cancers15245889. 2023
Delving into the clinical impact of NETs in pediatric cancer.
Benavent N; (...); Medina P
Article. 10.1038/s41390-024-03437-4. 2024
ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer.
Juan-Ribelles A; (...); Fernández-Teijeiro A
Article. 10.1007/s12094-024-03445-0. 2024
Evaluation of circulating tumor DNA by electropherogram analysis and methylome profiling in high-risk neuroblastomas
Trinidad, Eva Maria; (...); de Mora, Jaime Font
Article. 10.3389/fonc.2023.1037342. 2023
Factors Influencing Implementation of the Survivorship Passport: The IT Perspective.
Chronaki C; (...); Haupt R
Article. 10.3233/SHTI220363. 2022
Germline variant in Ctcf links mental retardation to Wilms tumor predisposition
Gargallo, Pablo; (...); Font de Mora, Jaime
Article. 10.1038/s41431-022-01105-x. 2022
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults.
Lopez-Briz, Eduardo; (...); Carbonell Sanchis, Rafael
Article. 10.1002/14651858.CD008462.pub4. 2022
HIGH RISK NEUROBLASTOMA (HR-NB) WITH MNA AND AGE
Ladenstein, Ruth; (...); Canete, Adela
Meeting Abstract. 2023
High risk neuroblastoma (HR-NB) with MNA and age <18 months: Results from the HR-NBL1/SIOPEN trial
Ladenstein, Ruth Lydia; (...); Canete, Adela
Meeting Abstract. 2023
Independent Validation of a Deep Learning nnU-Net Tool for Neuroblastoma Detection and Segmentation in MR Images
Veiga-Canuto, Diana; (...); Marti-Bonmati, Luis
Article. 10.3390/cancers15051622. 2023
INDIRECT COMPARISONS AND NETWORK META-ANALYSIS IN SPANISH DRUG POSITIONING REPORTS FOR PRICE AND FINANCING
Ortega, A.; (...); Lopez-Briz, E.
Meeting Abstract. 2024
International benchmarking of childhood cancer survival by tumour stage: First results of the BENCHISTA project
Pritchard-Jones, K.; (...); Gatta, G.
Meeting Abstract. 2024
International benchmarking of stage at diagnosis for six childhood solid tumours (the BENCHISTA project): a population-based, retrospective cohort study.
Botta, Laura; (...); Pritchard-Jones, Kathy
Article. 10.1016/S2352-4642(24)00302-X. 2025
IT-Related Barriers and Facilitators to the Implementation of a New European eHealth Solution, the Digital Survivorship Passport (SurPass Version 2.0): Semistructured Digital Survey.
de Beijer, Ismay A E; (...); Chronaki, Catherine
Article. 10.2196/49910. 2024
Lateral-type posterior fossa ependymomas in pediatric population
Miranda-Lloret, Pablo; (...); Llavador, Gemma
Article. 10.1016/j.neucir.2023.10.002. 2024
Lateral-type posterior fossa ependymomas in pediatric population.
Miranda-Lloret, Pablo; (...); Llavador, Gemma
Article. 10.1016/j.neucie.2023.10.001. 2024
Liquidhope: methylome and genomic profiling from very limited quantities of plasma-derived DNA.
Trinidad EM; (...); Font de Mora J
Article. 10.1093/bib/bbac575. 2023
Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.
Vázquez Polo A; (...); Vázquez Costa JF
Article. 10.20960/nh.03946. 2022
Medical and Public Health Imperatives of Xylazine.
López-Briz E, Olcina-Rodríguez JF
Letter. 10.1056/NEJMc2308155. 2023
Modeling Cardiotoxicity in Pediatric Oncology Patients Using Patient-Specific iPSC-Derived Cardiomyocytes Reveals Downregulation of Cardioprotective microRNAs.
Reinal, Ignacio; (...); Sepulveda, Pilar
Article. 10.3390/antiox12071378. 2023
MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.
Rodriguez D; (...); Jaspan T
Article. 10.1148/radiol.211464. 2022
Neuroblastoma in Spain: Linking the national clinical database and epidemiological registries - A study by the Joint Action on Rare Cancers.
Cañete A; (...); Spanish Neuroblastoma Linkage Working Group (SpNbLinkWG)
Article. 10.1016/j.canep.2022.102145. 2022
NUTRARET: Effect of 2-Year Nutraceutical Supplementation on Redox Status and Visual Function of Patients With Retinitis Pigmentosa: A Randomized, Double-Blind, Placebo-Controlled Trial
Olivares-Gonzalez, Lorena; (...); Rodrigo, Regina
Article. 10.3389/fnut.2022.847910. 2022
Patient benefit as a goal of humanization
David Gil-Sierra, Manuel, del Pilar Briceno-Casado, Maria, Lopez-Briz, Eduardo
Article. 10.7399/fh.13171. 2022
Personalized Medicine in Infant Population with Cancer: Pharmacogenetic Pilot Study of Polymorphisms Related to Toxicity and Response to Chemotherapy.
Urtasun, Andrea; (...); Herrero, Maria Jose
Article. 10.3390/cancers15051424. 2023
Pharmacotherapeutic management of advanced therapy medicinal products
Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia
Article. 10.7399/fh.13036. 2022
Prognostic factors of early mortality in children and adolescents enrolled in oncology trials with a dose-finding part in the era of targeted and immune therapies: An Innovative Therapies for Children with Cancer (ITCC) study
Carceller, Fernando; (...); Moreno, Lucas
Meeting Abstract. 2023
Radiotherapy quality assurance in paediatric clinical trials: first report from six QUARTET-affiliated trials.
Kelly, Sarah M.; (...); Mandeville, Henry
Article. 10.1016/j.radonc.2023.109549. 2023
Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A)
Lassaletta, Alvaro; (...); Juan-Ribelles, Antonio
Meeting Abstract. 2023
Regorafenib Plus Vincristine and Irinotecan in Pediatric Patients With Recurrent/Refractory Solid Tumors: An Innovative Therapies for Children With Cancer Study.
Casanova M; (...); Geoerger B
Article. 10.1158/1078-0432.CCR-23-0257. 2023
Reproducibility Analysis of Radiomic Features on T2-weighted MR Images after Processing and Segmentation Alterations in Neuroblastoma Tumors.
Veiga-Canuto, Diana; (...); Marti-Bonmati, Luis
Article. 10.1148/ryai.230208. 2024
Results of a survey on the treatment of adolescents and young adult (AYA) sarcoma patients in Spain at present time.
Mata Fernandez, Cristina; (...); Morales CV
Article. 10.1007/s12094-022-02912-w. 2022
Safety and PK (pharmacokinetic) profile of niraparib (nir) plus dostarlimab (dost) in pediatric patients (pts) with recurrent or refractory (RR) solid tumors: SCOOP study
Doz, Francois; (...); Rubio-San-Simon, Alba
Meeting Abstract. 2023
Scaling up and implementing the digital Survivorship Passport tool in routine clinical care - The European multidisciplinary PanCareSurPass project.
Filbert AL; (...); Haupt R
Article. 10.1016/j.ejca.2024.114029. 2024
Suprarenal Masses in Very Young Infants: Is It Safe to Watch and Wait? Report of a SIOPEN Observational Study Results
Papadakis, Vassilios; (...); Canete, Adela
Article. 10.3390/cancers14164007. 2022
Survival and Health Care Burden of Children With Retinoblastoma in Europe.
Virgili G; (...); Gatta G
Article. 10.1001/jamaophthalmol.2024.4140. 2024
THE BENCHISTA PROJECT: INTERNATIONAL BENCHMARKING OF CHILDHOOD CANCER SURVIVAL BY TUMOUR STAGE
Cortes, Angela Lopez; (...); Pritchard-Jones, Kathy
Article. 2022
The relevance of therapeutic positioning in the post-approval evaluation of new medicines.
Alegre-Del Rey EJ; (...); Domínguez-Santana CM
Article. 10.1016/j.farma.2024.06.001. 2024
Tumour growth: An approach to calibrate parameters of a multiphase porous media model based on in vitro observations of Neuroblastoma spheroid growth in a hydrogel microenvironment.
Hervas-Raluy, Silvia; (...); Wall, Wolfgang A.
Article. 10.1016/j.compbiomed.2023.106895. 2023
Vitronectin Levels in the Plasma of Neuroblastoma Patients and Culture Media of 3D Models: A Prognostic Circulating Biomarker?
Lopez-Carrasco, Amparo; (...); Noguera, Rosa
Article. 10.3390/ijms25168733. 2024